Vaccines for Older Adults: Current Practices and Future Opportunities

Editor(s): Weinberger, Birgit (Innsbruck)

The Future of Vaccines for the Older Population

Novel Technologies to Improve Vaccines for Older Adults

Laupèze B.a · van der Most R.a · Del Giudice G.b

Author affiliations

aGSK, Wavre, Belgium
bGSK, Siena, Italy

Related Articles for ""
Weinberger B (ed): Vaccines for Older Adults: Current Practices and Future Opportunities. Interdiscip Top Gerontol Geriatr. Basel, Karger, 2020, vol 43, pp 218–233
https://doi.org/10.1159/000504485

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of The Future of Vaccines for the Older Population

Received: September 12, 2018
Accepted: March 08, 2019
Published online: April 09, 2020
Cover Date: 2019

Number of Print Pages: 16
Number of Figures: 1
Number of Tables: 2

ISBN: 978-3-318-06677-7 (Print)
eISBN: 978-3-318-06678-4 (Online)

Abstract

Vaccine development has traditionally been driven by the need to prevent high numbers of childhood deaths due to infectious disease. With few exceptions, vaccines for adults are the same as vaccines for infants, although it has long been apparent that they become less effective as age increases. It is only in the last few years that concerted efforts have commenced to develop life-long vaccination strategies through into older age. Impressive progress has been made in the field of vaccine technologies which, when they will be applied to vaccination of older adults, could change the landscape for disease prevention in this age group. The recently licensed adjuvanted herpes zoster vaccine shows that immunosenescence need not be a barrier to highly effective vaccination, and that highly effective vaccines for older adults can be achieved with good vaccine design. One of the greatest public health challenges of the 21st century is ensuring the health and well-being of the aged. New or improved vaccines targeting pathogens with a high disease burden in older adults have the potential to major contributions to the longevity and productivity of the older aged population.

© 2020 S. Karger AG, Basel



Related Articles:

References

  1. United Nations, Department of Economic and Social Affairs, Population Division: World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP/248. 2017. Available at: https://esa.un.org/unpd/wpp/Publications/Files/WPP2017_KeyFindings.pdf. (accessed June 18, 2018).
  2. Tu W, Rao S: Mechanisms underlying T cell immunosenescence: aging and cytomegalovirus infection. Front Microbiol 2016;7:2111.
  3. Franceschi C, Salvioli S, Garagnani P, et al: Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Front Immunol 2017;8:982.
  4. Fulop T, Larbi A, Dupuis G, et al: Immunosenescence and inflammaging as two sides of the same coin: friends or foes? Front Immunol 2017;8:1960.
  5. Fourati S, Cristescu R, Loboda A, et al: Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat Commun 2016;7:10369.
  6. Van Der Meeren O, Crasta P, Cheuvart B, et al: Characterization of an age-response relationship to GSK’s recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum Vaccin Immunother 2015;11:1726–1729.
  7. Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH: High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 2013;58:262–264.
  8. Weston WM, Friedland LR, Wu X, et al: Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized trials. Vaccine 2012;30:1721–1728.
  9. Demicheli V, Jefferson T, Di Pietrantonj C, et al: Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2018;CD004876.
  10. Moberley S, Holden J, Tatham DP, et al: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;CD000422.
  11. Bonten MJ, Huijts SM, Bolkenbaas M, et al: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114–1125.
  12. Yawn BP, Gilden D: The global epidemiology of herpes zoster. Neurology 2013;81:928–930.
  13. Oxman MN, Levin MJ, Johnson GR, et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–2284.
  14. ZOSTAVAX® (Zoster Vaccine Live). Product information. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM132831.pdf (accessed April 19, 2017).
  15. Cunningham AL, Lal H, Kovac M, et al: Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019–1032.
  16. Lal H, Cunningham AL, Godeaux O, et al: Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087–2096.
  17. Del Giudice G, Goronzy JJ, Grubeck-Loebenstein B, et al: Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging. NPJ Aging Mech Dis 2017;4:1.
  18. Black S, De Gregorio E, Rappuoli R: Developing vaccines for an aging population. Sci Transl Med 2015;7:281ps288.
  19. Delany I, Rappuoli R, De Gregorio E: Vaccines for the 21st century. EMBO Mol Med 2014;6:708–720.
  20. DiazGranados CA, Dunning AJ, Kimmel M, et al: Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635–645.
  21. Robertson CA, DiazGranados CA, Decker MD, et al: Fluzone(R) high-dose influenza vaccine. Expert Rev Vaccines 2016;15:1495–1505.
  22. Marra F, Young F, Richardson K, et al: A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses 2013;7:584–603.
  23. Arakane R, Annaka R, Takahama A, et al: Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: a randomized controlled phase III study. Vaccine 2015;33:6650–6658.
  24. O’Hagan DT, Ott GS, De Gregorio E, et al: The mechanism of action of MF59 – an innately attractive adjuvant formulation. Vaccine 2012;30:4341–4348.
  25. Domnich A, Arata L, Amicizia D, et al: Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine 2017;35:513–520.
  26. Garçon N, Vaughn DW, Didierlaurent AM: Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012;11:349–366.
  27. Nicholson KG, Abrams KR, Batham S, et al: Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011;11:91–101.
  28. McElhaney JE, Beran J, Devaster J-M, et al: AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013;13:485–496.
  29. Lecrenier N, Beukelaers P, Colindres R, et al: Development of a recombinant adjuvanted herpes zoster subunit vaccine and its implications for shingles prevention. Expert Rev Vaccines, in press.
  30. McElhaney JE, Lal H, Cunningham A, et al: Efficacy, immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine in adults aged 60 years and older: results from the ZOE-50 and ZOE-70 efficacy studies. IDWeek, New Orleans, October 2016.
  31. Santosham M, Reid R, Ambrosino DM, et al: Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 1987;317:923–929.
  32. Feldman MF, Wacker M, Hernandez M, et al: Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 2005;102:3016–3021.
  33. Lee CJ: Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry. Biologicals 2002;30:97–103.
  34. Ihssen J, Kowarik M, Dilettoso S, et al: Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 2010;9:61.
  35. Riddle M, Kaminski R, Di Paolo C, et al: Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single blind, randomized phase I study. Clin Vaccine Immunol 2016;23:908–917.
  36. Huttner A, Hatz C, van den Dobbelsteen G, et al: Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis 2017;17:528–537.
  37. Wacker M, Wang L, Kowarik M, et al: Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 2014;209:1551–1561.
  38. Poolman JT, Wacker M: Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis 2016;213:6–13.
  39. Pinschewer DD: Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med Wkly 2017;147:w14465.
  40. Humphreys IR, Sebastian S: Novel viral vectors in infectious diseases. Immunology 2018;153:1–9.
  41. Lauer KB, Borrow R, Blanchard TJ: Multivalent and multipathogen viral vector vaccines. Clin Vaccine Immunol 2017;24:e00298-16.
  42. Vitelli A, Folgori A, Scarselli E, et al: Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane. Expert Rev Vaccines 2017;16:1241–1252.
  43. Chen RT, Carbery B, Mac L, et al: The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine 2015;33:73–75.
  44. Ramezanpour B, Haan I, Osterhaus A, et al: Vector-based genetically modified vaccines: exploiting Jenner’s legacy. Vaccine 2016;34:6436–6448.
  45. Ulmer JB, Mansoura MK, Geall AJ: Vaccines “on demand”: science fiction or a future reality. Expert Opin Drug Discov 2015;10:101–106.
  46. Lutz J, Lazzaro S, Habbeddine M, et al: Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2017;2:29.
  47. Sette A, Rappuoli R: Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010;33:530–541.
  48. Giuliani MM, Adu-Bobie J, Comanducci M, et al: A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834–10839.
  49. Parikh SR, Andrews NJ, Beebeejaun K, et al: Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet 2016;388:2775–2782.
  50. Liljeroos L, Malito E, Ferlenghi I, et al: Structural and computational biology in the design of immunogenic vaccine antigens. J Immunol Res 2015;2015:156241.
  51. McLellan JS, Chen M, Joyce MG, et al: Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013;342:592–598.
  52. Fleming DM, Taylor RJ, Lustig RL, et al: Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis 2015;15:443.
  53. Kim HW, Canchola JG, Brandt CD, et al: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422–434.
  54. Higgins D, Trujillo C, Keech C: Advances in RSV vaccine research and development – a global agenda. Vaccine 2016;34:2870–2875.
  55. Tappero JW, Lagos R, Ballesteros AM, et al: Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520–1527.
  56. Gerke C, Colucci AM, Giannelli C, et al: Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS One 2015;10:e0134478.
  57. Launay O, Lewis DJM, Anemona A, et al: Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine 2017;22:164–172.
  58. Obiero CW, Ndiaye AGW, Scire AS, et al: A phase 2a randomized study to evaluate the safety and immuno­genicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front Immunol 2017;8:1884.
  59. Lee TK, Hutter JN, Masel J, et al: Guidelines for the prevention of travel-associated illness in older adults. Trop Dis Travel Med Vaccines 2017;3:10.
  60. Williams WW, Lu PJ, O’Halloran A, et al: Surveillance of vaccination coverage among adult populations – United States, 2015. MMWR Surveill Summ 2017;66:1–28.
  61. Mourits VP, Wijkmans JC, Joosten LA, et al: Trained immunity as a novel therapeutic strategy. Curr Opin Pharmacol 2018;41:52–58.
  62. DiazGranados CA, Dunning AJ, Robertson CA, et al: Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine 2015;33:4565–4571.
  63. Cunningham AL, Lal H, Kovac M, et al: Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019–1032.
  64. Bloom DE, Black S, Salisbury D, Rappuoli R: Antimicrobial resistance and the role of vaccines. Proc Natl Acad Sci USA 2018;115:12868–12871.
  65. Bagnoli F, Fontana MR, Soldaini E, et al: Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci USA 2015;112:3680–3685.
  66. RSV Vaccine and mAb Snapshot. Available at: https://path.azureedge.net/media/documents/RSV-snapshot-2018Dec_High_Resolution_V3.pdf.

Article / Publication Details

First-Page Preview
Abstract of The Future of Vaccines for the Older Population

Received: September 12, 2018
Accepted: March 08, 2019
Published online: April 09, 2020
Cover Date: 2019

Number of Print Pages: 16
Number of Figures: 1
Number of Tables: 2

ISBN: 978-3-318-06677-7 (Print)
eISBN: 978-3-318-06678-4 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

Table of Contents

Article

Recommend This
TOP